title: A nitric oxide synthase inhibitor decreases 6-hydroxydopamine effects on tyrosine hydroxylase and neuronal nitric oxide synthase in the rat nigrostriatal pathway.
abstract: There is evidence that nitric oxide plays a role in the neurotransmitter balance within the basal ganglia and in the pathology of Parkinson's disease. In the present work we investigated in striatal 6-hydroxydopamine (6-OHDA) lesioned rats the effects of a nitric oxide synthase (NOS) inhibitor, NG-nitro-l-arginine (L-NOARG), given systemically on both the dopaminergic (DA) neuronal loss and the neuronal NOS cell density. We analyzed the DA neuronal loss through tyrosine hydroxylase immunohistochemistry (TH). The nitrergic system was evaluated using an antibody against the neuronal NOS (nNOS) isoform. Treatment with the L-NOARG significantly reduced 6-OHDA-induced dopaminergic damage in the dorsal striatum, ventral substantia nigra and lateral globus pallidus, but had no effects in the dorsal substantia nigra and in the cingulate cortex. Furthermore, L-NOARG reduced 6-OHDA-induced striatal increase, and substantia nigra compacta decrease, in the density of neuronal nitric oxide synthase positive cells. These results suggest that nitric oxide synthase inhibition may decrease the toxic effects of 6-OHDA on dopaminergic terminals and on dopamine cell bodies in sub-regions of the SN and on neuronal nitric oxide synthase cell density in the rat brain.
authors.affiliation: Department of Physiology, FORP, University of São Paulo, Av. Café S/N, 14040-904 Ribeirão Preto, SP, Brazil.
authors.forename: Margarete Zanardo
authors.initials: MZ
authors.lastname: Gomes
authors.forename: Rita
authors.initials: R
authors.lastname: Raisman-Vozari
authors.forename: Elaine A
authors.initials: EA
authors.lastname: Del Bel
mesh_terms: D018663:Adrenergic Agents / Q000494:pharmacology; D000704:Analysis of Variance; D000818:Animals; D002452:Cell Count / Q000379:methods; D003342:Corpus Striatum / Q000187:drug effects* / Q000201:enzymology; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D008297:Male; D009434:Neural Pathways / Q000187:drug effects / Q000201:enzymology; D052248:Nitric Oxide Synthase Type I / Q000378:metabolism*; D019335:Nitroarginine / Q000494:pharmacology*; D016627:Oxidopamine / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D013378:Substantia Nigra / Q000187:drug effects* / Q000201:enzymology; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism*
chemical_list: D018663:Adrenergic Agents; D004791:Enzyme Inhibitors; D019335:Nitroarginine; D016627:Oxidopamine; D052248:Nitric Oxide Synthase Type I; D014446:Tyrosine 3-Monooxygenase